Randomization: Patients will be treated with either flecainide or sotalol for 3 months and then cross over to the alternate drug for 3 months. The order of assignment will be randomly assigned using a permuted block design with alternate block sizes of 2 and 4 subjects. The randomization list will be generated by the PI and provided to the Investigational Drug Service (IDS) pharmacy. The study will be open-label.